In the SURMOUNT-1 trial, obese patients without diabetes who received tirzepatide with monthly lifestyle counseling lost 20.9% of baseline weight at 72 weeks (versus 3.1% for placebo) with ...

The results from a sub-population of patients in Lilly's SURMOUNT-1 trial suggest that tirzepatide could provide an alternative that, at least in theory, could require less dramatic lifestyle changes.

Please provide your email address to receive an email when new articles are posted on . A post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials found that early responders to tirzepatide, or ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

Tirzepatide has been studied in weight management in 2 large, phase 3 studies: SURMOUNT‑1 (n=2,539) in people who did not have diabetes and SURMOUNT‑2 (n=938) in people with type 2 diabetes. Both ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Novo is fighting to maintain share against competitor Eli Lilly's Zepbound, which yielded a similar 20.1% placebo-adjusted weight loss at 72 weeks in the Surmount-1 study and showed superiority to ...